Unstable angina pectoris
Conditions
Interventions
Control group:Guidelines for secondary prevention of coronary heart disease+placebo
Experimental group:Guidelines recommended secondary prevention drugs for coronary heart disease + Luohengfang Chinese medicine treatment
Sponsors
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 75 years old, regardless of gender; 2. Patients with coronary heart disease confirmed by coronary angiography or coronary CTA (stenosis =50% of one or more major coronary arteries), or positive exercise treadmill test, or old history of myocardial infarction; 3. The frequency of angina pectoris attacks is greater than 2 times per week, and the angina pectoris grade is between I-III; 4. Agree to correct follow-up, collection of specimens and medication arrangement during the follow-up period; 5. I and my family members agree to the treatment plan and sign the informed consent. 6. Healthy subjects have no chronic diseases in the past, no abnormalities in blood routine, blood biochemistry, physical examination, electrocardiogram and other examinations, and sign informed consent.(YNMT)·
Exclusion criteria
Exclusion criteria: 1. Patients with chronic kidney disease combined with severe heart, lung, liver and other vital organ dysfunction; Serious primary diseases such as hematopoietic system and/or severe heart, lung, liver and other vital organ dysfunction; 2. Patients with severe uncontrolled hypertension (systolic blood pressure =180mmHg or diastolic blood pressure =110mmHg); 3. Severe arrhythmias (ventricular tachycardia, ventricular fibrillation, grade III atrioventricular block, cardiac arrest, severe sinus tachycardia and bradycardia, sick sinus syndrome, reentrant supraventricular tachycardia, hemodynamic changes caused by arrhythmia); 4. Cancer or other systemic diseases with an expected survival of <12 months; 5. Allergy, or food allergy to a variety of drugs, or known allergy to the ingredients of drugs; 6. Pregnant or lactating women; 7. Patients with mental, psychological and other problems that do not match study completion. 8. People who have a history of special drugs or are taking special drugs and may affect the treatment results; 9.3 Participants who have participated in other clinical trials within the last month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seattle Angina Pectoris Scale (SAQ); | — |
Secondary
| Measure | Time frame |
|---|---|
| Angina symptom score;TCM symptom score;ECG ST segment changes;Cardiac function evaluation; | — |
Countries
China
Contacts
Public ContactXian Wang
The First Clinical Medical School of Beijing University of Chinese Medicine
Outcome results
None listed